MAY 07, 2015 2:21 PM PDT

Personal Profiling for Womb Cancer

WRITTEN BY: Ilene Schneider
About 2.8 percent of women will be diagnosed with endometrial cancer at some point in their lives, according to the National Cancer Institute. Contributing factors to the disease, in which malignant cells form in the tissues of the endometrium, include hormone therapy, obesity, high blood pressure and diabetes mellitus (http://seer.cancer.gov/statfacts/html/corp.html).
Genetic profiling of endometrial cancer can lead to more effective treatment.
The American Cancer Society says that cancer of the endometrium - the lining of the uterus or womb -- is the most common cancer of the female reproductive organs. The organization projects that in 2015 approximately 54,870 new cases of cancer of the body of the uterus (uterine body or corpus, including the endometrium) will be diagnosed, and 10,170 women will die from such cancers (http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-what-is-endometrial-cancer ).

Until now patients with endometrial cancer were classified as to their risk of disease in terms of a combination of clinical and tissue characteristics, such as their age, overall health data and the "growth and invasion of their tumor," according to researchers at the University of Manchester. Now these researchers can genetically profile high-risk womb cancer patients, enabling the patients to receive more appropriate treatment (University of Manchester. "Potential for a more personalized approach to womb cancer." ScienceDaily. ScienceDaily, 7 May 2015; www.sciencedaily.com/releases/2015/05/150507081741.htm).

While approximately 15 to 20 percent of endometrial cancer patients have high-risk disease, the optimal treatment approach for them has not been evident. The Manchester researchers have been studying genetic alterations in high-risk endometrial cancer, to determine whether they could be used to develop tumor subtypes. The team included Professor Richard Edmondson, Professor of Gynecological Oncology at The University of Manchester and Saint Mary's Hospital, as well as Dr Emma Crosbie and Professor Henry Kitchener from Manchester.

According to Prof. Edmondson, "Previous work, using comprehensive genetic profiling, has suggested that endometrial cancer can be classified into four subtypes. Our study has explored whether it is possible to use a simpler approach to detect subgroups in high risk patients."

Analyzing samples from 116 patients with endometrial cancer to find genetic variations, the international TransPORTEC research consortium discovered that genetic subtypes existed in their group of patients and that the classification procedure could predict which patients were more likely to relapse. The analysis enabled the researchers to identify distinctive genetic mutations that they could target with specific anti-cancer drugs.

Prof. Edmondson concluded, "It looks like these cancers classed as 'high-risk' in fact vary significantly in outcome. Our results could be used to refine risk assessment for endometrial cancer patients and allow doctors to choose either a less aggressive approach or more targeted treatment for individual patients." (University of Manchester. "Potential for a more personalized approach to womb cancer." ScienceDaily. ScienceDaily, 7 May 2015. www.sciencedaily.com/releases/2015/05/150507081741.htm).

Source: University of Manchester
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
NOV 24, 2019
Drug Discovery & Development
NOV 24, 2019
The Fight Against Lethal Childhood Brain Cancers
Scientists used studies on cell and animal models to reveal insights into lethal childhood brain cancers and find promising drug therapeutics. The deadly c...
DEC 06, 2019
Health & Medicine
DEC 06, 2019
Study finds association between hair products and breast cancer risk
For many women, hair color and style are significant components of their identity. However, troubling information from a new study about the use of hair dy...
DEC 25, 2019
Drug Discovery & Development
DEC 25, 2019
New Drug to Make Breast Cancer Treatment More Affordable
The US Food and Drug Administration has granted accelerated approval to new breast cancer drug, trastuzumab deruxtecan. The drug’s increasing recogni...
JAN 07, 2020
Clinical & Molecular DX
JAN 07, 2020
Saliva Test for Early Detection of Mouth and Throat Cancer
“OPC is one of the fastest rising cancers in Western countries due to increasing HPV-related incidence, especially in younger patients. It is paramou...
JAN 15, 2020
Cell & Molecular Biology
JAN 15, 2020
Cell Division Research Reveals More About a Protein That's Elevated in Cancer
Cell division is a carefully regulated process, cancer is the result when it gets out of control....
JAN 23, 2020
Cancer
JAN 23, 2020
The role of circular RNA in melanoma
New research published in the journal Cancer Cell investigates the role of circular RNAs in the spread of melanoma. Melanoma is a particularly aggressive c...
Loading Comments...